Highest-materiality recent filing
IDEXX shareholders approve board declassification and 25% special meeting right
Board declassification approved; all directors to be elected annually starting at 2029 annual meeting.
IDEXX Q1 beats: rev $1.14B (+14%), EPS $3.47 (+17%); raises FY guidance
Q1 revenue $1,141M (+14% as reported, +11% organic); EPS $3.47 (+17% as reported, +15% comparable).
IDEXX EVP Nimrata Hunt to depart Apr 13; position eliminated, advisory role until Jul 13
Nimrata Hunt, EVP Global Strategy & Commercial, steps down effective Apr 13, 2026; position eliminated.
Director M. Anne Szostak to retire from IDEXX Board effective May 12, 2026
Szostak notified Board on Feb 13, 2026; retirement effective after 2026 Annual Meeting.
IDEXX Q4 revenue $1.09B (+14% YoY), EPS $3.08 (+18%); guides FY26 rev $4.63B-$4.72B
Q4 revenue $1,091M (+14% as reported, +12% organic); EPS $3.08 (+18% as reported, +17% comparable).
Jay Mazelsky steps down as CEO effective May 12, 2026, transitions to Executive Chair; will retire from board in May 2027.
IDEXX amends credit facility: extends revolver to 2030, adds $250M term loan due 2028
Amendment extends $1.0B revolver maturity to 5 years from Nov 12, 2025; adds $250M term loan due 3 years from closing.
IDEXX Q3 revenue $1.1B (+13%), EPS $3.40 (+21%); raises FY2025 guidance
Revenue $1,105M (+13% reported, +12% organic); CAG Diagnostics recurring revenue +11% reported, +10% organic.
IDEXX elects Karen Peacock as independent Class I director
Karen Peacock elected independent Class I director, effective October 6, 2025, filling a newly created seat.
IDEXX Q2 EPS $3.63 (+49% reported); raises FY2025 revenue and EPS guidance
Q2 revenue $1,109M (+11% reported, +9% organic); CAG Diagnostics recurring revenue +9% reported, +7% organic.
IDEXX elects former State Street CEO Joseph L. Hooley to Board; board expands to 10
Joseph L. (Jay) Hooley elected as independent Class III Director effective July 10, 2025.
IDEXX shareholders approve charter amendments removing supermajority, officer exculpation
Filed Certificate of Elimination for Series A Preferred Stock; preferred shares revert to undesignated status.
IDEXX Q1 EPS $2.96 (+5%), rev $998M (+4%); raises FY25 revenue & EPS outlook
Q1 revenue $998M (+4% reported, +5% organic); EPS $2.96 (+5%, +7% comparable).
IDEXX director Asha Collins resigns from Board, effective immediately
Dr. Asha Collins resigned from the Board of Directors on February 13, 2025.
IDEXX Q4 revenue $954M (+6% YoY), EPS $2.62; guides 2025 rev $4.06-$4.17B, EPS $11.74-$12.24
Q4 revenue $954M (+6% reported and organic); CAG Diagnostics recurring revenue +7% organic.
Participants may defer 5–50% of base salary, 5–100% of annual bonus, and 5–100% of stock units.
IDEXX boosts share repurchase authorization by 5M shares, adds to 1.3M remaining
Board authorized repurchase of up to five million additional shares of common stock.
IDEXX CFO Brian McKeon to retire June 2025; Andrew Emerson named successor effective March 1, 2025
McKeon will retire June 1, 2025; will step down as CFO March 1, 2025 and serve as Special Advisor until retirement.
Board member Jonathan W. Ayers resigns from IDEXX Board effective Nov 8, 2024
Ayers resigned from Board and Finance Committee effective November 8, 2024.
IDEXX extends Ortho-Clinical Diagnostics supply agreement to 2044, revises pricing
IDEXX entered U.S. and European supply agreement amendments with Ortho-Clinical Diagnostics for dry slides used in veterinary chemistry analyzers.
IDEXX corrects FY24 comparable margin expansion to 30-60 bps (from 70-100 bps); Q3 EPS $2.80
Corrected 2024 comparable operating profit margin expansion to 30-60 bps from 70-100 bps (error in prior release).
IDEXX Q3 EPS $2.80, revenue $976M; cuts FY24 revenue guidance citing macro headwinds
Q3 revenue $976M (+7% reported, +6% organic); EPS $2.80 (+11% reported, +12% comparable).
IDEXX Q2 rev +6% to $1,004M; EPS $2.44; cuts FY guidance on litigation charge
Revenue $1,004M, +6% reported (+7% organic); CAG Diagnostics recurring +6% reported (+7% organic).
IDEXX enters $25K/month consulting pact with retired EVP; all annual meeting proposals pass
Retired EVP James Polewaczyk to provide coaching; $25,000/month for one-year term starting May 7, 2024.
IDEXX Q1 revenue $964M (+7%), EPS $2.81; cuts 2024 revenue/EPS guidance on FX and visit slowdown
Q1 revenue $964M (+7% as reported and organic); EPS $2.81 (+10% reported, +9% comparable).
IDEXX Q4 revenue $902M (+9%); FY24 guides $3.93-4.04B, EPS $10.84-11.33
Q4 revenue $902M, up 9% reported and 8% organic; CAG Diagnostics recurring revenue +11% reported and +10% organic.
IDEXX EVP and Chief Commercial Officer James Polewaczyk to retire April 1, 2024
James F. Polewaczyk, EVP and Chief Commercial Officer, notified retirement on Dec 5, 2023.
IDEXX Q3 revenue $916M (+9% reported); EPS $2.53; FY guidance updated to $3.635-$3.65B
Q3 revenue $916M (+9% reported, +8% organic) driven by CAG Diagnostics recurring revenue +10% reported (+9% organic).
IDEXX Q2 revenue $944M (+10% organic); EPS $2.67 (+71%); raises 2023 guidance
Q2 revenue $944M, +10% reported and organic; CAG Diagnostics recurring revenue +11% reported, +12% organic.
IDEXX Laboratories elects Irene Chang Britt to Board of Directors
Irene Chang Britt elected as independent Class I Director, effective July 11, 2023.
IDEXX shareholders re-elect three Class II directors and approve say-on-pay at 2023 annual meeting
Directors Junius, Kingsley, and Vandebroek elected as Class II directors with >61M votes each.
IDEXX Q1 revenue $900M (+8% reported, +10% organic); EPS $2.55; raises 2023 guidance
Q1 revenue $900M, up 8% reported, 10% organic; CAG Diagnostics recurring revenue up 9% reported, 12% organic.
IDEXX Q4 revenue +7% organic; EPS $2.05; FY23 guidance rev $3.59B-$3.69B, EPS $9.27-$9.75
Q4 revenue $829M (+3% reported, +7% organic); EPS $2.05 (+8% reported, +14% comparable).
IDEXX Q3 revenue $842M (+8% organic); EPS $2.15 (+13% comparable); updates FY2022 guidance
Q3 revenue $842M, +4% reported, +8% organic; CAG Diagnostics recurring revenue +5% reported, +9% organic.
IDEXX amends credit agreement, adds $250M term loan and SOFR conversion
Borrowed $250M incremental term loan on Oct 20, 2022 under amended credit facility.
IDEXX Q2 revenue $861M +4% reported; EPS $1.56 -33%; cuts FY2022 guidance
Revenue $861M, up 4% reported and 6.5% organic; CAG Diagnostics recurring revenue +4% reported, +7% organic.
IDEXX amends bylaws to align director nomination notice with SEC Rule 14a-19
Amended Section 1.10 to require stockholders to represent they intend to solicit proxies from holders of at least 67% of voting power.
IDEXX to wind down Russian subsidiary, end direct operations
Revenue from Russia represented less than 1% of total 2021 consolidated revenue.
All four Class III director nominees (Ayers, Essig, Mazelsky, Szostak) elected; Mazelsky received 69.9M votes for.
IDEXX Q1 rev $837M (+8%); cuts FY22 EPS guidance to $8.11-$8.35 on vet capacity, forex, R&D charge
Q1 EPS $2.27 (-3% reported, +3% comparable); revenue $837M (+8% reported and organic).
IDEXX Q4 revenue $801M (+11%), full-year EPS $8.60 (+28%); guides 2022 revenue $3.5-$3.565B
Q4 revenue $801M, up 11% reported and 10.5% organic; CAG Diagnostics recurring revenue grew 13%.
IDEXX enters $1B revolving credit facility with extended maturity and lower rates
Fourth amended & restated credit agreement provides $1B unsecured revolver with $250M accordion feature.
IDEXX Q3 revenue $810M (+12%), EPS $2.03; raises FY2021 guidance to higher end
Q3 revenue $810M (+12% reported, +10% organic); EPS $2.03 (+20% reported, +12% comparable).
IDEXX Q2 revenue $826M (+30% reported, +25% organic); raises FY 2021 guidance
EPS of $2.34, up 36% as reported and 33% comparable basis.
On February 13, 2025, Dr. Asha Collins resigned from the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), effective immediately.
Brian P. McKeon, Executive Vice President, Chief Financial Officer and Treasurer of IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) notified the Company that he will retire from IDEXX effective June 1, 2025.
the Board appointed Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance of the Company, as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective March 1, 2025.
On November 8, 2024, Jonathan W. Ayers, a member of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), resigned from the Board and its finance committee, effective November 8, 2024.
On December 5, 2023, James F. Polewaczyk, Executive Vice President and Chief Commercial Officer of IDEXX Laboratories, Inc. (the “Company”), notified the Company of his intent to retire after more than 17 years of dedicated leadership and service, effective April 1, 2024.
On July 11, 2023 the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Irene Chang Britt as an independent Class I Director
Max materiality 0.85 · Median 0.65 · Most common event earnings